BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 121844)

  • 1. [Beta-1,3-glucan and other immunomodulators in experimental leprosy infection in mice].
    Delville J; Jacques PJ
    Acta Leprol; 1979; (76-77):273-81. PubMed ID: 121844
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of beta-1,3 glucan and other immunomodulators of microbial origin on experimental leprosy in mice].
    Rayyan W; Delville J
    Acta Leprol; 1983; 1(2):93-100. PubMed ID: 6356766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [beta-1, 3 glucan as an immunopotentiator against experimental tuberculous infection in mice (author's transl)].
    Kanai K; Kondo E
    Kekkaku; 1980 Aug; 55(8):371-4. PubMed ID: 7420811
    [No Abstract]   [Full Text] [Related]  

  • 4. Anthrax-protective effects of yeast beta 1,3 glucans.
    Kournikakis B; Mandeville R; Brousseau P; Ostroff G
    MedGenMed; 2003 Mar; 5(1):1. PubMed ID: 12827062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of glucan and other immunopharmacological agents in the prevention and treatment of acute radiation injuries.
    Patchen ML; Chirigos MA; Brook I
    Fundam Appl Toxicol; 1988 Nov; 11(4):573-4. PubMed ID: 3229582
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experimental studies on the use of an immunoadjuvant (beta-1, 3 glucan) to prevent relapse after termination of chemotherapy in mouse model (author's transl)].
    Kondo E; Kanai K
    Kekkaku; 1980 Sep; 55(9):411-4. PubMed ID: 7431726
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear beta-1,3-D-glucan and other immunomodulators in murine cells.
    Morikawa K; Takeda R; Yamazaki M; Mizuno D
    Cancer Res; 1985 Apr; 45(4):1496-501. PubMed ID: 3156669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies on the prevention of insulin-dependent diabetes mellitus by immunomodulation: lessons from NOD mice treated with beta-1,6;1,3-D-glucan and rhIGF-I.
    Kida K; Kaino Y; Ito T; Hirai H
    J Pediatr Endocrinol Metab; 1998 Apr; 11 Suppl 2():327-33. PubMed ID: 9642663
    [No Abstract]   [Full Text] [Related]  

  • 9. [Further study of immunopotentiation in experimental antiblastic therapy by inactivated yeasts and glucan].
    Delfina Pesce C; Boccanera M; Marconi P; Bistoni F; Cenci E; Tissi L; Cassone A
    Ann Ist Super Sanita; 1982; 18(3):509-12. PubMed ID: 7187836
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydrogen peroxide as a tumoricidal mediator of murine polymorphonuclear leukocytes induced by a linear beta-1,3-D-glucan and some other immunomodulators.
    Morikawa K; Kamegaya S; Yamazaki M; Mizuno D
    Cancer Res; 1985 Aug; 45(8):3482-6. PubMed ID: 2990672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of beta-1,3-glucan to prevent shipping fever in imported heifers.
    Pedroso M
    Arch Med Res; 1994; 25(2):181. PubMed ID: 7919809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation of protozoan diseases. Potential of glucan as an adjuvant.
    Cook JA; Runey GL; Holbrook TW
    Surv Immunol Res; 1983; 2(3):243-5. PubMed ID: 6675146
    [No Abstract]   [Full Text] [Related]  

  • 13. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan).
    de Felippe Júnior J; da Rocha e Silva Júnior M; Maciel FM; Soares Ade M; Mendes NF
    Surg Gynecol Obstet; 1993 Oct; 177(4):383-8. PubMed ID: 8211583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta glucan vs bacterial infections - continuous daily use of yeast-derived beta glucan is questioned.
    Posit Health News; 1998; (No 17):22-3. PubMed ID: 11366551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sequential multi-assay protocol for the preclinical assessment of natural product complex carbohydrate immunomodulators.
    Williams DL; Pretus HA; McNamee RB; Jones EL
    Dev Biol Stand; 1992; 77():129-36. PubMed ID: 1426653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopharmacological studies of beta-1,3-glucan.
    Ríos-Hernández M; Dos-Santos NJ; Silvia-Cardoso ; Bello-Gárciga JL; Pedroso M
    Arch Med Res; 1994; 25(2):179-80. PubMed ID: 7919808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endotoxemia is masked in fungal infection due to enhanced endotoxin clearance by beta-glucan.
    Yokota M; Tsujinaka T; Kambayashi J; Watase M; Sakon M; Mori T
    Int Surg; 1991; 76(4):255-60. PubMed ID: 1778725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.
    Cheung NK; Modak S; Vickers A; Knuckles B
    Cancer Immunol Immunother; 2002 Nov; 51(10):557-64. PubMed ID: 12384807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
    Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
    J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.